CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.990
-0.190 (-5.97%)
Jun 5, 2026, 3:01 PM EDT - Market open
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $10.26M in the quarter ending March 31, 2026, a decrease of -79.85%. This brings the company's revenue in the last twelve months to $35.54M, down -75.91% year-over-year. In the year 2025, CytomX Therapeutics had annual revenue of $76.20M, down -44.82%.
Revenue (ttm)
$35.54M
Revenue Growth
-75.91%
P/S Ratio
18.31
Revenue / Employee
$515,101
Employees
69
Market Cap
650.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 76.20M | -61.90M | -44.82% |
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
| Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
| Dec 31, 2017 | 71.62M | 58.78M | 457.59% |
| Dec 31, 2016 | 12.85M | 6.90M | 116.21% |
| Dec 31, 2015 | 5.94M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 888.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| Zevra Therapeutics | 122.29M |
| Oculis Holding AG | 1.40M |
| Avalo Therapeutics | 59.00K |
| Allogene Therapeutics | 22.00K |
CTMX News
- 1 day ago - CytomX Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 days ago - CytomX Therapeutics expands licensing agreement with Regeneron - TheFly
- 2 days ago - CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer - GlobeNewsWire
- 15 days ago - CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewsWire
- 17 days ago - CytomX Therapeutics initiated with an Outperform at Wolfe Research - TheFly
- 18 days ago - CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs - GlobeNewsWire
- 25 days ago - CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright - TheFly
- 4 weeks ago - CytomX Therapeutics reports Q1 EPS (10c), consensus (11c) - TheFly